Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oren Hershkovitz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.47
- Country
- IL
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.58
Financials
Net Income
$1.24BEBITDA
$-5.79MFree Cash Flow
$-2.91MEPS (diluted)
$386.85Shares Outstanding (diluted)
3.21M+13225.7%Operating Expenses
$5.75MCash & Debt
$5.87MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $1.24B | $405.60 |
| 2024 | $0.00 | $-15.01M | $-10.95 |
| 2023 | $0.00 | $-29.07M | $-23.40 |
| 2022 | $0.00 | $-31.06M | $-34.65 |
| 2021 | $0.00 | $-14.47M | $-8.10 |
| 2020 | $2.28M | $-11.82M | $-15.75 |
| 2019 | $0.00 | $-9.38M | $-17.55 |
| 2018 | $0.00 | $-4.24M | $-159.45 |
| 2017 | $0.00 | $-5.95M | $-215.25 |
| 2016 | $0.00 | $-16.02M | $-604.35 |
| 2015 | $0.00 | $-15.37M | $-647.85 |
| 2014 | $0.00 | $-7.02M | $-343.65 |
| 2013 | $0.00 | $-1.15M | $-63.15 |
| 2012 | $0.00 | $-229.0K | $-0.13 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $595.91
- Implied price
- $10,726
- Return from $1.27
- 510.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5,333 — today's price is already 100.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 410.4% | 433.7% | 453.5% | 470.8% | 486.3% |
| 3.0% | 436.4% | 460.9% | 481.8% | 500.0% | 516.2% |
| 8.0% | 462.5% | 488.2% | 510.0% | 529.1% | 546.1% |
| 13.0% | 488.5% | 515.4% | 538.2% | 558.2% | 576.0% |
| 18.0% | 514.6% | 542.6% | 566.5% | 587.3% | 606.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newszacks.com·5h ago·Negative
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
View source ↗
Earnings
Fri, Sep 4(in 2 days)
Consensus estimate $-0.31 per share
Typical surprise +15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Mar 30$-3.45 vs $-0.45miss
- Wed, Mar 25$410.25 vs $-1.29beat
- Fri, Nov 14$-1.35 vs $-1.80beat
- Fri, Aug 29$-1.20 vs $-2.40beat
- Fri, May 30$-2.25 vs $-2.40beat
- Mon, Mar 31$-3.45 vs $-2.40miss
Estimates and results for ENLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENLV officers and directors.
- Bought
- —
- Sold
- $157k
0 trades
1 trade
- Murray Michael Anthonysold
29 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.